Welcome to the e-CCO Library!

P421: Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liebert, A.(1);Kłopocka, M.(1);Cichoż-Lach, H.(2);Michalak, A.(2);Talar-Wojnarowska, R.(3);Domżał-Magrowska, D.(3);Filipiuk, A.(4);Krogulecki, M.(4);Kopertowska-Majchrzak, M.(5);Eder, P.(6);Stawczyk-Eder, K.(6);Waszak, K.(6);Zagórowicz, E.(7,8);Wojciechowski, K.(9,10);Drygała, S.(9)*;
Created: Friday, 14 July 2023, 11:05 AM
P421: SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Misra1, J. Curran2, H. Herfarth3, K. Jagarlamudi4, C. Oneto5, B.R. Bhandari6, G. Wiener7, D. Kerman8, A. Moss9, R. Pomerantz10, J. Zhao10, P. Bernardo10, S. Simmons10, L. Diao10, E. O’Brien10, M. Henn10, M. Trucksis10*

Created: Thursday, 21 February 2019, 9:14 AM
P421: Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Juzlova1, K. Koblova1, J. Herzogova1, M. Bortlik*2, D. Duricova2, M. Lukas2

Created: Friday, 22 February 2019, 9:49 AM
P421: Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Attauabi, M.(1,2,3);Vind, I.(1,3);Pedersen, G.(1,3);Bendtsen, F.(3);Benedict Seidelin, J.(2);Burisch, J.(1,3);
Created: Wednesday, 2 June 2021, 4:12 PM
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cremer1, T. Lobaton2, S. Vieujan3, P. Bossuyt4, J.F. Rahier5, F. Baert6, O. Dewit7, M. Somers8, E. Macken8, A. Vijverman9, P. Van Hootegem10, F. Mana11, B. Willandt12, P. Caenepeel13, E. Humblet13, F. D’Heygere14, A. Verreth15, A. El Nawar16, J.L. Coenegrachts17, S. Dewit18, S. De Coninck19, N. Schoofs20, S. Delen21, J. Dutre22, C. Thienpont23, S. Vanden Branden24, D. Staessen25, D. Franchimont1, Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group

Created: Thursday, 30 January 2020, 10:12 AM
P422: COVID 19 infection in IBD patients treated with biologic therapy-experience from tertiary center in Serbia
Year: 2021
Source: ECCO'21 Virtual
Authors: Sokic Milutinovic, A.(1);Jevtovic, M.(2);Jovicic, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P422: How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
Year: 2022
Source: ECCO'22
Authors: Routledge, E.(1);Meade, S.(1);Sharma, E.(1);Zeki, S.(1);Ray, S.(1);Anderson, S.(1);Sanderson, J.(1);Mawdsley, J.(1);Samaan, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P422: Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Alten*1, C. Markland2, K. Kawakami3, M. Boyce4, F. Casty5, R. Muniz5, M. C. Genovese6

Created: Friday, 22 February 2019, 9:41 AM
P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assay
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Roseth A.*1, Lindsjô I.2, Malmstrøm G.-H.3

Created: Wednesday, 20 February 2019, 10:36 AM
P422: Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. W. Lee, C. H. Choi*

Created: Friday, 22 February 2019, 9:49 AM
P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.V. Loftus1, B.E. Sands2, J.-F. Colombel3, I. Dotan4, J.M. Khalid5, D. Tudor6, P. Geransar7*

Created: Thursday, 21 February 2019, 9:14 AM
P422: Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Todeschini, A.(1)*;Geccherle, A.(1);Signoretto, P.(1);Fasoli, E.(1);Variola, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Radigina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, S. Petrichuk1, A.P. Fisenko1

Created: Thursday, 30 January 2020, 10:12 AM
P423: Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.
Year: 2022
Source: ECCO'22
Authors: Ranjan, M.K.(1);Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Sharma, R.(1);Panwar, R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:52 PM
P423: Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Subramanian*1, R. Davis1, P. MacParland1, S. Dodd2, D. Storey1, C. Probert1, P. Collins1, T. Skouras1, A. Steel1, E. Derbyshire1, M. Dibb1

Created: Friday, 22 February 2019, 9:41 AM
P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Casellas F.*1, Barreiro-de Acosta M.2, Esteve M.3, Castro-Laria L.4, Vicente R.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Boudet J.M.5, Rodríguez-San Pedro L.13, Díaz G.13, Casado R.13, Marín I.14

Created: Wednesday, 20 February 2019, 10:36 AM
P423: Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Romeo, S.(1)*;Carvalhas Gabrielli, A.M.(1);Ferretti, F.(2);Piazza O Sed, N.(3);Mazzola, A.M.(4);Alicante, S.(1);Berté, R.(1);Scribano, M.L.(5);Buscarini, E.(1);Ricci, C.(4);Caprioli, F.(3,6);Ardizzone, S.(2);Cannatelli, R.(2);
Created: Friday, 14 July 2023, 11:05 AM
P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Chaparro1,2,3,4*, J.L. Cabriada5, M.J. Casanova1,2,4, D. Ceballos6, M. Esteve4,7, H. Fernández8, M. Barreiro-de Acosta9, V. García-Sánchez10,11, D. Ginard12, F. Gomollón4,13,14, R. Llorente Poyatos15, P. Nos4,16, S. Riestra17, M. Rivero18, P. Robledo19, C. Rodríguez Gutiérrez20, B. Sicilia21, E. Torrella22, F. Rodríguez-Artalejo23,24,25, J.P. Gisbert1,2,3,4, on behalf of the EpidemIBD group

Created: Thursday, 21 February 2019, 9:14 AM
P423: Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Olbjørn*1, 2, J. B. Rove1, J. Jahnsen2, 3

Created: Friday, 22 February 2019, 9:49 AM
P423: Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapies
Year: 2021
Source: ECCO'21 Virtual
Authors: Picker, N.(1);Patel, H.(2);Wilke, T.(3);Rosin, L.(4);Bokemeyer, B.(5);
Created: Wednesday, 2 June 2021, 4:12 PM